Trump Revokes Biden's Order to Lower Drug Prices for Medicare
Biden's Executive Order to lower copays for some drugs to $2 for Medicare and Medicaid enrollees is nixed by President Trump.


President Donald Trump has been busy rescinding Biden-era Executive Orders in his first days in office, including one that had the potential to lower the cost of prescription drugs for Americans on Medicare.
Known as Executive Order 14087, it was designed to identify a list of prescription drugs that would, under the plan, require only a $2 copay a month for anyone on Medicare. Former President Biden had directed the Center for Medicare and Medicaid Innovation, an arm of the Centers for Medicare and Medicaid Services, to look into ways to make prescription drugs cheaper for Medicare recipients.
“Too many Americans face challenges paying for prescription drugs. On average, Americans pay two to three times as much as people in other countries for prescription drugs, and one in four Americans who take prescription drugs struggle to afford their medications,” Biden said at the time. “Nearly 3 in 10 American adults who take prescription drugs say that they have skipped doses, cut pills in half, or not filled prescriptions due to cost.”

Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Lowering drugs costs for Medicare enrollees
Drugs that were identified to be included on the Medicare $2 Drug List Model included ones to treat diabetes, high cholesterol and thyroid issues. The model aimed to “standardize cost sharing for low-cost generics through a new, easy-to-understand option for people with Medicare Part D enrolled in a participating plan and their health care providers,” wrote CMS when originally announcing the plan.
Other parts of the executive order included improving access to cell and gene therapies, which have high costs associated with them, and accelerating the evidence-gathering process for new drugs. Trump’s new executive order would take those mandates away from CMS.
More Medicare changes in the works?
In rescinding Biden’s executive order on prescription drugs and many others, Trump said, “The previous administration has embedded deeply unpopular, inflationary, illegal, and radical practices within every agency and office of the Federal Government.” He warned, “The revocations within this order will be the first of many steps the United States Federal Government will take to repair our institutions and our economy.” Other Medicare and Medicaid existing laws and regulations around prescription drugs remain in effect for now.
It's unclear what Trump will do about Medicare's ability to negotiate lower drug prices under the Inflation Reduction Act, put on the books in 2022. The Act allows Medicare to negotiate drug prices directly with pharmaceutical companies for the first time. President Trump hasn’t said if he supports the government’s ability to negotiate with the drug companies directly.
In the first round, Medicare negotiated lower prices for ten drugs. Last week, Medicare announced that it planned to negotiate prices for another 15 medications, including the popular weight-loss drugs Ozempic and Wegovy. The high costs associated with these drugs, which have proven effective, have been fiercely criticized by consumers.
Related content
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.

Donna Fuscaldo is the retirement writer at Kiplinger.com. A writer and editor focused on retirement savings, planning, travel and lifestyle, Donna brings over two decades of experience working with publications including AARP, The Wall Street Journal, Forbes, Investopedia and HerMoney.
-
How to Turn Your Retirement Dreams into Reality (Despite Your Fears)
Stressing over shrinking savings, rising healthcare costs, or losing your purpose can give you chills, but smart money moves can lead to financial freedom and a happy retirement.
-
Figma IPO: Should You Buy FIG Stock?
The Figma IPO has plenty of buzz building around it, with the design software company expected to start trading next week.
-
How to Turn Your Retirement Dreams into Reality (Despite Your Fears)
Stressing over shrinking savings, rising healthcare costs, or losing your purpose can give you chills, but smart money moves can lead to financial freedom and a happy retirement.
-
Your Online Security: 10 Things You Should Know
Online security is more tenuous given the rise of AI. Arm yourself against internet criminals with these tips to strengthen online security.
-
A Financial Planner's Prescription for the Headache of Multiple Retirement Accounts
Having a bunch of retirement accounts can cause unnecessary complications. Consolidation can make it easier to manage your savings and potentially improve investment outcomes.
-
Overpaying for Financial Advice? A Financial Planner's Guide to Fees
Take five minutes to review how much you're paying for financial advice. If you're overpaying, you could be better off with an adviser who charges a flat fee.
-
The Big Red Bucket Theory: A Financial Adviser's Simple Way to Visualize Your Retirement Plan
When you think about retirement, picture a big red bucket brimming with all the money you've saved. It's everything you've got, and it has to last you.
-
Thinking of Getting a New Car in Retirement? Why GM's Latest News Matters
The retirement car conundrum: buy outright or finance your next ride?
-
Denmark Raised the Social Security Age to 70. Should the US Do the Same?
Social Security is facing a shortfall. One idea is to raise the retirement age, as Denmark did recently, but would it work in America?
-
Why Splurging in Retirement is Totally Worth It
Splurging on yourself is okay when it fits your budget, as it can enhance your happiness and reward your hard work without compromising financial security.